Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05555342 · ClinicalTrials.gov registry record · Early Phase 1
A Novel Method for Treating Lung Met w/Combo of Electric Fields & Rad Therapy: A Single-Arm
A Early Phase 1 study of Metastatic Cancer and Lung Tumor, sponsored by University of California, Irvine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT05555342 is a Early Phase 1 study of Metastatic Cancer and Lung Tumor that has completed, run by University of California, Irvine. The registered enrollment target is 6 participants, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05555342, a Early Phase 1 study of Metastatic Cancer and Lung Tumor, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 0, pilot prospective study to determine the feasibility of combined irreversible electroporation (IRE) and radiation therapy in subjects with lung tumors with metastatic cancer of any histology. These are subjects who have advanced disease (stage IV) or previously treated disease that has become progressive, recurrent, or metastatic.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- PROCEDURE Irreversible electroporation (IRE) ablation
Study Locations (1)
California
- Chao Family Comprehensive Cancer Center University of California, Irvine - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2023-01-03 |
| Est. Completion | 2024-10-27 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05555342
The ClinicalTrials.gov registry entry for NCT05555342 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (99% lower). The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Radiation Therapy is the first listed.
NCT05555342 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05555342 about?
NCT05555342 is a clinical study titled "A Novel Method for Treating Lung Met w/Combo of Electric Fields & Rad Therapy: A Single-Arm". This is a phase 0, pilot prospective study to determine the feasibility of combined irreversible electroporation (IRE) and radiation therapy in subjects with lung tumors with metastatic cancer of any histology. These are subjects who have advanced disease (stage IV) or previously treated disease tha...
What is the current status of trial NCT05555342?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2023-01-03. Estimated completion is 2024-10-27.
What conditions does trial NCT05555342 study?
This clinical trial studies the following conditions: Metastatic Cancer, Lung Tumor.
What interventions are being tested in trial NCT05555342?
The interventions under investigation include: Radiation Therapy (RADIATION), Irreversible electroporation (IRE) ablation (PROCEDURE).
Who is sponsoring clinical trial NCT05555342?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05555342 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
RECRUITING · Early Phase 1
-
Evaluating Disparities in Precision Oncology
RECRUITING
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
RECRUITING · Phase 2
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.